报价延迟最少15分钟:2026/05/10 15:12 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
83.03 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-4.22/-5.39
|
|
企业价值
6.17B
|
| 资产负债 |
|
每股账面净值
12.00
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for thetreatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies bytargeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties. |
